Castle Biosciences

CSTL

Market cap $1.15B

39.51 USD

-3.33

7.77%

At close Updated Jan 28, 4:00 PM EST

Pre-market

After hours

39.51

0.00

1 day

-7.77%

5 days

-4.15%

1 month

0.61%

3 months

63.6%

6 months

141.95%

Year to date

2.52%

1 year

46.01%

5 years

-42.33%

10 years

84.63%

About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Employees: 823

Healthcare Diagnostics & Research